Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/novartis-subsidy-promise-with-rider-17107/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/novartis-subsidy-promise-with-rider-17107/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/novartis-subsidy-promise-with-rider-17107/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/novartis-subsidy-promise-with-rider-17107/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-trace').style.display = (document.getElementById('cakeErr680da58a99c9d-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680da58a99c9d-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-code').style.display = (document.getElementById('cakeErr680da58a99c9d-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-context').style.display = (document.getElementById('cakeErr680da58a99c9d-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680da58a99c9d-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680da58a99c9d-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 16979,
		&#039;title&#039; =&gt; &#039;Novartis subsidy promise with rider&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;
&lt;br /&gt;
But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;
&lt;br /&gt;
Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;
&lt;br /&gt;
In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;
&lt;br /&gt;
The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;
&lt;br /&gt;
Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;
&lt;br /&gt;
Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;
&lt;br /&gt;
A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;
&lt;br /&gt;
Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 13 September, 2012, http://www.telegraphindia.com/1120913/jsp/nation/story_15971206.jsp#.UFE_t64XVwc&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;novartis-subsidy-promise-with-rider-17107&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 17107,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 16979,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Novartis subsidy promise with rider&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;&lt;br /&gt;But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;&lt;br /&gt;Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;&lt;br /&gt;In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;&lt;br /&gt;The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;&lt;br /&gt;Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;&lt;br /&gt;Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;&lt;br /&gt;A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;&lt;br /&gt;Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 16979,
	&#039;title&#039; =&gt; &#039;Novartis subsidy promise with rider&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;
&lt;br /&gt;
But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;
&lt;br /&gt;
Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;
&lt;br /&gt;
In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;
&lt;br /&gt;
The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;
&lt;br /&gt;
Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;
&lt;br /&gt;
Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;
&lt;br /&gt;
A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;
&lt;br /&gt;
Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 13 September, 2012, http://www.telegraphindia.com/1120913/jsp/nation/story_15971206.jsp#.UFE_t64XVwc&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;novartis-subsidy-promise-with-rider-17107&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 17107,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 16979
$metaTitle = &#039;LATEST NEWS UPDATES | Novartis subsidy promise with rider&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;&lt;br /&gt;But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;&lt;br /&gt;Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;&lt;br /&gt;In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;&lt;br /&gt;The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;&lt;br /&gt;Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;&lt;br /&gt;Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;&lt;br /&gt;A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;&lt;br /&gt;Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/novartis-subsidy-promise-with-rider-17107.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Novartis subsidy promise with rider | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Novartis subsidy promise with rider</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.<br /><br />But the court described its scheme of classifying people on the basis of their incomes as &ldquo;too complicated&rdquo; and again urged the company to reduce prices.<br /><br />Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.<br /><br />In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.<br /><br />The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.<br /><br />Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).<br /><br />Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.<br /><br />A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &ldquo;too unaffordable&rdquo;.<br /><br />NGOs, health activists and generic drug makers are opposing the company&rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.<br /><br />Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-trace').style.display = (document.getElementById('cakeErr680da58a99c9d-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680da58a99c9d-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-code').style.display = (document.getElementById('cakeErr680da58a99c9d-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-context').style.display = (document.getElementById('cakeErr680da58a99c9d-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680da58a99c9d-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680da58a99c9d-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 16979,
		&#039;title&#039; =&gt; &#039;Novartis subsidy promise with rider&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;
&lt;br /&gt;
But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;
&lt;br /&gt;
Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;
&lt;br /&gt;
In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;
&lt;br /&gt;
The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;
&lt;br /&gt;
Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;
&lt;br /&gt;
Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;
&lt;br /&gt;
A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;
&lt;br /&gt;
Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 13 September, 2012, http://www.telegraphindia.com/1120913/jsp/nation/story_15971206.jsp#.UFE_t64XVwc&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;novartis-subsidy-promise-with-rider-17107&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 17107,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 16979,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Novartis subsidy promise with rider&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;&lt;br /&gt;But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;&lt;br /&gt;Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;&lt;br /&gt;In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;&lt;br /&gt;The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;&lt;br /&gt;Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;&lt;br /&gt;Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;&lt;br /&gt;A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;&lt;br /&gt;Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 16979,
	&#039;title&#039; =&gt; &#039;Novartis subsidy promise with rider&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;
&lt;br /&gt;
But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;
&lt;br /&gt;
Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;
&lt;br /&gt;
In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;
&lt;br /&gt;
The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;
&lt;br /&gt;
Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;
&lt;br /&gt;
Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;
&lt;br /&gt;
A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;
&lt;br /&gt;
Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 13 September, 2012, http://www.telegraphindia.com/1120913/jsp/nation/story_15971206.jsp#.UFE_t64XVwc&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;novartis-subsidy-promise-with-rider-17107&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 17107,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 16979
$metaTitle = &#039;LATEST NEWS UPDATES | Novartis subsidy promise with rider&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;&lt;br /&gt;But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;&lt;br /&gt;Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;&lt;br /&gt;In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;&lt;br /&gt;The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;&lt;br /&gt;Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;&lt;br /&gt;Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;&lt;br /&gt;A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;&lt;br /&gt;Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/novartis-subsidy-promise-with-rider-17107.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Novartis subsidy promise with rider | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Novartis subsidy promise with rider</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.<br /><br />But the court described its scheme of classifying people on the basis of their incomes as &ldquo;too complicated&rdquo; and again urged the company to reduce prices.<br /><br />Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.<br /><br />In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.<br /><br />The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.<br /><br />Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).<br /><br />Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.<br /><br />A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &ldquo;too unaffordable&rdquo;.<br /><br />NGOs, health activists and generic drug makers are opposing the company&rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.<br /><br />Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-trace').style.display = (document.getElementById('cakeErr680da58a99c9d-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680da58a99c9d-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-code').style.display = (document.getElementById('cakeErr680da58a99c9d-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680da58a99c9d-context').style.display = (document.getElementById('cakeErr680da58a99c9d-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680da58a99c9d-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680da58a99c9d-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 16979,
		&#039;title&#039; =&gt; &#039;Novartis subsidy promise with rider&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;
&lt;br /&gt;
But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;
&lt;br /&gt;
Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;
&lt;br /&gt;
In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;
&lt;br /&gt;
The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;
&lt;br /&gt;
Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;
&lt;br /&gt;
Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;
&lt;br /&gt;
A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;
&lt;br /&gt;
Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 13 September, 2012, http://www.telegraphindia.com/1120913/jsp/nation/story_15971206.jsp#.UFE_t64XVwc&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;novartis-subsidy-promise-with-rider-17107&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 17107,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 16979,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Novartis subsidy promise with rider&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;&lt;br /&gt;But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;&lt;br /&gt;Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;&lt;br /&gt;In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;&lt;br /&gt;The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;&lt;br /&gt;Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;&lt;br /&gt;Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;&lt;br /&gt;A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;&lt;br /&gt;Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 16979,
	&#039;title&#039; =&gt; &#039;Novartis subsidy promise with rider&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;
&lt;br /&gt;
But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;
&lt;br /&gt;
Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;
&lt;br /&gt;
In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;
&lt;br /&gt;
The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;
&lt;br /&gt;
Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;
&lt;br /&gt;
Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;
&lt;br /&gt;
A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;
&lt;br /&gt;
NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;
&lt;br /&gt;
Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 13 September, 2012, http://www.telegraphindia.com/1120913/jsp/nation/story_15971206.jsp#.UFE_t64XVwc&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;novartis-subsidy-promise-with-rider-17107&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 17107,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 16979
$metaTitle = &#039;LATEST NEWS UPDATES | Novartis subsidy promise with rider&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.&lt;br /&gt;&lt;br /&gt;But the court described its scheme of classifying people on the basis of their incomes as &amp;ldquo;too complicated&amp;rdquo; and again urged the company to reduce prices.&lt;br /&gt;&lt;br /&gt;Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.&lt;br /&gt;&lt;br /&gt;In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.&lt;br /&gt;&lt;br /&gt;The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.&lt;br /&gt;&lt;br /&gt;Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).&lt;br /&gt;&lt;br /&gt;Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.&lt;br /&gt;&lt;br /&gt;A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&amp;rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&amp;rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &amp;ldquo;too unaffordable&amp;rdquo;.&lt;br /&gt;&lt;br /&gt;NGOs, health activists and generic drug makers are opposing the company&amp;rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.&lt;br /&gt;&lt;br /&gt;Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/novartis-subsidy-promise-with-rider-17107.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Novartis subsidy promise with rider | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Novartis subsidy promise with rider</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.<br /><br />But the court described its scheme of classifying people on the basis of their incomes as &ldquo;too complicated&rdquo; and again urged the company to reduce prices.<br /><br />Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.<br /><br />In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.<br /><br />The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.<br /><br />Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).<br /><br />Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.<br /><br />A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &ldquo;too unaffordable&rdquo;.<br /><br />NGOs, health activists and generic drug makers are opposing the company&rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.<br /><br />Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 16979,
		'title' => 'Novartis subsidy promise with rider',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph<br />
<br />
Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.<br />
<br />
But the court described its scheme of classifying people on the basis of their incomes as &ldquo;too complicated&rdquo; and again urged the company to reduce prices.<br />
<br />
Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.<br />
<br />
In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.<br />
<br />
The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.<br />
<br />
Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).<br />
<br />
Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.<br />
<br />
A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &ldquo;too unaffordable&rdquo;.<br />
<br />
NGOs, health activists and generic drug makers are opposing the company&rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.<br />
<br />
Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. <br />
</div>',
		'credit_writer' => 'The Telegraph, 13 September, 2012, http://www.telegraphindia.com/1120913/jsp/nation/story_15971206.jsp#.UFE_t64XVwc',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'novartis-subsidy-promise-with-rider-17107',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 17107,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 16979,
	'metaTitle' => 'LATEST NEWS UPDATES | Novartis subsidy promise with rider',
	'metaKeywords' => 'medicines,Health',
	'metaDesc' => '
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But...',
	'disp' => '<div align="justify">-The Telegraph<br /><br />Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.<br /><br />But the court described its scheme of classifying people on the basis of their incomes as &ldquo;too complicated&rdquo; and again urged the company to reduce prices.<br /><br />Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.<br /><br />In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.<br /><br />The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.<br /><br />Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).<br /><br />Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.<br /><br />A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &ldquo;too unaffordable&rdquo;.<br /><br />NGOs, health activists and generic drug makers are opposing the company&rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.<br /><br />Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. <br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 16979,
	'title' => 'Novartis subsidy promise with rider',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph<br />
<br />
Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.<br />
<br />
But the court described its scheme of classifying people on the basis of their incomes as &ldquo;too complicated&rdquo; and again urged the company to reduce prices.<br />
<br />
Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.<br />
<br />
In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.<br />
<br />
The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.<br />
<br />
Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).<br />
<br />
Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.<br />
<br />
A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &ldquo;too unaffordable&rdquo;.<br />
<br />
NGOs, health activists and generic drug makers are opposing the company&rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.<br />
<br />
Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. <br />
</div>',
	'credit_writer' => 'The Telegraph, 13 September, 2012, http://www.telegraphindia.com/1120913/jsp/nation/story_15971206.jsp#.UFE_t64XVwc',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'novartis-subsidy-promise-with-rider-17107',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 17107,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 16979
$metaTitle = 'LATEST NEWS UPDATES | Novartis subsidy promise with rider'
$metaKeywords = 'medicines,Health'
$metaDesc = '
-The Telegraph

Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.

But...'
$disp = '<div align="justify">-The Telegraph<br /><br />Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched.<br /><br />But the court described its scheme of classifying people on the basis of their incomes as &ldquo;too complicated&rdquo; and again urged the company to reduce prices.<br /><br />Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices.<br /><br />In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid.<br /><br />The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines.<br /><br />Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000).<br /><br />Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug.<br /><br />A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company&rsquo;s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis&rsquo;s claim for a patent. Novartis has also contested a board finding that the price was &ldquo;too unaffordable&rdquo;.<br /><br />NGOs, health activists and generic drug makers are opposing the company&rsquo;s claim to any patent that would prevent cheaper generic versions from being produced for the poor.<br /><br />Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims. <br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Novartis subsidy promise with rider

-The Telegraph Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched. But the court described its scheme of classifying people on the basis of their incomes as “too complicated” and again urged the company to reduce prices. Whatever the scheme, the end result of all business transactions is financial results, the bench said. The court had asked the company yesterday too to cut prices. In an affidavit today, Novartis said should it get a patent and prices are not touched, it would continue its patient assistance scheme in the country till 2018, covering the period the patent is valid. The company said it was providing the drug free or at subsidised prices to patients who meet specific medical and socio-economic guidelines. Novartis claimed that no patient in India has to pay for more than 80 days of the annual cost of Glivec. It claimed only 5 per cent have to pay a part of the annual cost ranging between 10 and 40 days of treatment (costing Rs 33,000-1,35,000). Not more than 1.5 per cent of total patients pay for 80 days of treatment (Rs 270,000). Novartis is seeking court intervention to overcome Section 3(d) of the Indian Patents Act, 1970, which disallows any patents on minor tinkering of existing patents. The company claims that Glivec is a breakthrough drug. A two-judge bench of Justices Aftab Alam and Ranjana Desai is hearing the company’s appeal against the Madras High Court order upholding the Indian Patents Appellate Board order disallowing Novartis’s claim for a patent. Novartis has also contested a board finding that the price was “too unaffordable”. NGOs, health activists and generic drug makers are opposing the company’s claim to any patent that would prevent cheaper generic versions from being produced for the poor. Cheap versions of the drug produced in India are used in over 68 countries, NGO Medicines Sans Frontiers claims.